Current management approaches to portopulmonary hypertension

International Journal of Clinical Practice

Volumn 65, Issue SUPPL. 169, 2011, Pages 11-18

  Savale, L ^a,b,c   OCallaghan, D S ^a,b,c   Magnier, R ^d   Le Pavec, J ^e   Herve P ^a,b,c,f   Jai X ^a,b,c   Seferian, A ^b   Humbert, M ^a,b,c   Simonneau, G ^a,b,c   Sitbon, O ^a,b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c Universite Paris Sud   (France)

^d CAEN UNIVERSITY HOSPITAL   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; ANTICOAGULANT AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; NITRIC OXIDE; OXYGEN; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTAGLANDIN DERIVATIVE; SILDENAFIL; UNIPROST; ENDOTHELIN RECEPTOR;

ANGIOGENESIS; CONFERENCE PAPER; CONTINUOUS INFUSION; DYSPNEA; ESOPHAGUS VARICES; GENETIC POLYMORPHISM; HUMAN; LIGATION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTOPULMONARY HYPERTENSION; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SURVIVAL; TRANSTHORACIC ECHOCARDIOGRAPHY; DRUG ANTAGONISM; HEMODYNAMICS; LUNG CIRCULATION; PHYSIOLOGY; REVIEW;

DIURETICS; HEMODYNAMICS; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE 5 INHIBITORS; PULMONARY CIRCULATION; RECEPTORS, ENDOTHELIN;

EID: 78650852523     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02600.x     Document Type: Conference Paper

References (56)

1. Hoeper M, Krowka M, Strassburg C,. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004; 363: 1461 - 8.
2. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43 - 54.
3. Hadengue A, Benhayoun M, Lebrec D, Benhamou J,. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991; 100: 520 - 8.
4. Colle I, Moreau R, Godinho E, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology 2003; 37: 401 - 9.
5. Halank M, Ewert R, Seyfarth H, Hoeffken G,. Portopulmonary hypertension. J Gastroenterol 2006; 41: 837 - 47.
6. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023 - 30.
7. Kawut S, Krowka M, Trotter J, et al. Clinical risk factors for portopulmonary hypertension. Hepatology 2008; 48: 196 - 203.
8. Roberts K, Fallon M, Krowka M, et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med 2009; 179: 835 - 42.
9. Le Pavec J, Souza R, Herve P, et al. Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med 2008; 178: 637 - 43.
10. Robalino B, Moodie D,. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 1991; 17: 492 - 8.
11. Kawut S, Taichman D, Ahya V, et al. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl 2005; 11: 1107 - 11.
12. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164 - 72.
13. Mandell M, Groves B,. Pulmonary hypertension in chronic liver disease. Clin Chest Med 1996; 17: 17 - 33.
14. O'Callaghan D, Gaine SP,. Hepatopulmonary syndromes: treatment of liver transplantation candidates. Curr Opin Org Transpl 2002; 7: 107 - 13.
15. Jones F, Kuo P, Johnson L, Njoku M, Dixon-Ferguson M, Plotkin J,. The coexistence of portopulmonary hypertension and hepatopulmonary syndrome. Anesthesiology 1999; 90: 626 - 9.
16. Hervé P, Lebrec D, Brenot F, et al. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998; 11: 1153 - 66.
17. Nunes H, Lebrec D, Mazmanian M, et al. Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats. Am J Respir Crit Care Med 2001; 164: 879 - 85.
18. Galiè N, Hoeper M, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219 - 63.
19. Kim W, Krowka M, Plevak D, et al. Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl 2000; 6: 453 - 8.
20. Rodríguez-Roisin R, Krowka M, Hervé P, Fallon M, Committee ETFP-HVDPS. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J 2004; 24: 861 - 80.
21. Provencher S, Herve P, Jais X, et al. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006; 130: 120 - 6.
22. Van der Linden P, Le Moine O, Ghysels M, Ortinez M, Devière J,. Pulmonary hypertension after transjugular intrahepatic portosystemic shunt: effects on right ventricular function. Hepatology 1996; 23: 982 - 7.
23. Ota K, Shijo H, Kokawa H, et al. Effects of nifedipine on hepatic venous pressure gradient and portal vein blood flow in patients with cirrhosis. J Gastroenterol Hepatol 1995; 10: 198 - 204.
24. Montani D, Savale L, Natali D, et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J 2010; 31: 1898 - 907.
25. Benjaminov FS, Prentice M, Sniderman KW, Siu S, Liu P, Wong F,. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut 2003; 52: 1355 - 62.
26. Chan C, Wang S, Lee F, et al. Endothelin-1 induces vasoconstriction on portal-systemic collaterals of portal hypertensive rats. Hepatology 2001; 33: 816 - 20.
27. Kojima H, Sakurai S, Kuriyama S, et al. Endothelin-1 plays a major role in portal hypertension of biliary cirrhotic rats through endothelin receptor subtype B together with subtype A in vivo. J Hepatol 2001; 34: 805 - 11.
28. Tièche S, De Gottardi A, Kappeler A, et al. Overexpression of endothelin-1 in bile duct ligated rats: correlation with activation of hepatic stellate cells and portal pressure. J Hepatol 2001; 34: 38 - 45.
29. O'Callaghan D, Gaine SP,. Bosentan: a novel agent for the treatment of pulmonary arterial hypertension. Int J Clin Pract 2004; 58: 69 - 73.
30. Kuntzen C, Gülberg V, Gerbes A,. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy? Gastroenterology 2005; 128: 164 - 8.
31. Halank M, Miehlke S, Hoeffken G, Schmeisser A, Schulze M, Strasser R,. Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension. Transplantation 2004; 77: 1775 - 6.
32. Grander W, Eller P, Fuschelberger R, Tilg H,. Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C. Eur J Clin Invest 2006; 36 (Suppl. 3): 67 - 70.
33. Stähler G, von Hunnius P,. Successful treatment of portopulmonary hypertension with bosentan: case report. Eur J Clin Invest 2006; 36 (Suppl. 3): 62 - 6.
34. Hoeper M, Halank M, Marx C, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005; 25: 502 - 8.
35. Savale L, Magnier R, Le Pavec J, et al. Impact Of pulmonary arterial hypertension specific therapy on portopulmonary hypertension. Am J Respir Crit Care Med 2010; 181: A3339.
36. Cartin-Ceba R, Swanson K, Iyer V, Wiesner R, Krowka M,. Safety and efficacy of Ambrisentan for the therapy of portopulmonary hypertension. Chest Aug 2010 [Epub ahead of print].
37. van Giersbergen P, Popescu G, Bodin F, Dingemanse J,. Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. J Clin Pharmacol 2003; 43: 15 - 22.
38. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148 - 57.
39. Reichenberger F, Voswinckel R, Steveling E, et al. Sildenafil treatment for portopulmonary hypertension. Eur Respir J 2006; 28: 563 - 7.
40. Gough MS, White RJ,. Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension. Liver Transpl 2009; 15: 30 - 6.
41. Hemnes AR, Robbins IM,. Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation. Liver Transpl 2009; 15: 15 - 9.
42. Krowka MJ, Swanson KL,. How should we treat portopulmonary hypertension? Eur Respir J 2006; 28: 466 - 7.
43. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296 - 302.
44. McLaughlin V, Genthner D, Panella M, Rich S,. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998; 338: 273 - 7.
45. Kuo P, Johnson L, Plotkin J, Howell C, Bartlett S, Rubin L,. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 1997; 63: 604 - 6.
46. Plotkin J, Kuo P, Rubin L, et al. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation 1998; 65: 457 - 9.
47. Krowka M, Frantz R, McGoon M, Severson C, Plevak D, Wiesner R,. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999; 30: 641 - 8.
48. O'Callaghan DS, Moutet A, Jais X, et al. Catheter related-infections in pulmonary hypertension patients treated by continuous intravenous epoprostenol: experience of the French Referral Centre. Am J Respir Crit Care Med 2010; 181: A3337.
49. Minder S, Fischler M, Muellhaupt B, et al. Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension. Eur Respir J 2004; 24: 703 - 7.
50. Halank M, Marx C, Miehlke S, Hoeffken G,. Use of aerosolized inhaled iloprost in the treatment of portopulmonary hypertension. J Gastroenterol 2004; 39: 1222 - 3.
51. Hoeper MM, Seyfarth HJ, Hoeffken G, et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J 2007; 30: 1096 - 102.
52. Melgosa M, Ricci G, García-Pagan J, et al. Acute and long-term effects of inhaled iloprost in portopulmonary hypertension. Liver Transpl 2010; 16: 348 - 56.
53. Swanson K, Wiesner R, Nyberg S, Rosen C, Krowka M,. Survival in portopulmonary hypertension: mayo Clinic experience categorized by treatment subgroups. Am J Transplant 2008; 8: 2445 - 53.
54. Fix O, Bass N, De Marco T, Merriman R,. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol. Liver Transpl 2007; 13: 875 - 85.
55. Budhiraja R, Hassoun P,. Portopulmonary hypertension: a tale of two circulations. Chest 2003; 123: 562 - 76.
56. Krowka M, Plevak D, Findlay J, Rosen C, Wiesner R, Krom R,. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000; 6: 443 - 50.